Information Provided By:
Fly News Breaks for October 17, 2019
SAGE
Oct 17, 2019 | 07:58 EDT
Jefferies analyst Michael Yee says recent market weakness has created a buying opportunity for shares of Sage Therapeutics. The analyst remains bullish ahead of the company's Phase III depression data. Positive data could push Sage's stock past $200 versus of downside of $80-$100 on negative results, Yee tells investors in a research note. Positive data could open up a $4B-$6B sales opportunity and also increase the likelihood of a Sage Therapeutics takeover, Yee adds. He keeps a Buy rating on the shares with a $195 price target.